OWC Pharmaceutical appoints chief scientific officer | S&P Global Market Intelligence

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
WebinarPractical steps to achieve net-zero underwriting – Set a baseline, define targets and take action
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am GMT
WebinarPolitics & Policy: Sustainability Measures and Physical Risks
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

OWC Pharmaceutical appoints chief scientific officer

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

A Cloud Migration Plan for Corporations featuring Snowflake®

Investor Activism Campaigns Hit Record High in 2022

Essential IR Insights Newsletter - February 2023

20 Feb, 2018 | 19:59

OWC Pharmaceutical appoints chief scientific officer

Author Kshitiz Goliya
Theme Healthcare & Pharmaceuticals

OWC Pharmaceutical Research Corp. appointed Oron Zeevi as chief scientific officer.

Previously, Zeevi served as chief scientific officer at NeuroDerm Ltd., which was bought by Mitsubishi Tanabe Pharma Corp. for $1.1 billion in 2017.